Quantcast

Adaptimmune T-cell Therapy


#1

For whoever doesn't know them yet, Adaptimmune is the company that genetically engineered T-cells to target NY-ESO in synovial sarcoma and melanoma. Their trial was initially at NIH and then extended to other locations:

https://clinicaltrials.gov/ct2/show/NCT01343043

Well, Adaptimmune released a lot of good news this week. They made a deal with GSK and now they were just granted breakthrough therapy designation by the FDA:

http://www.adaptimmune.com/news-events/

So far in their studies, only patients who were HLA-A2 positive could participate so many people were not eligible. It looks like they will try to develop the technology so it works for other HLA types which is great news.


#2

The results from the NY-ESO-1 targeting T cells trial from Adaptimmune will be presented at ASCO in June. You can find the abstract here:
http://abstracts.asco.org/199/AbstView_199_193450.html


Etoposide versus Doxorubicin plus Olaratumab or Other Options